Get the Stockscreener App
36.20
0.22%
-0.08
Roivant Sciences Ltd stock is traded at $36.20, with a volume of 4.53M.
It is down -0.22% in the last 24 hours and up +3.70% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$36.28
Open:
$36.135
24h Volume:
4.53M
Relative Volume:
0.75
Market Cap:
$26.15B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-71.88
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
-0.39%
1M Performance:
+3.70%
6M Performance:
+36.86%
1Y Performance:
+208.09%
1-Day Range:
$35.87
$36.49
1-Week Range:
$34.56
$36.78
52-Week Range:
$11.54
$37.00
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
36.20 | 26.12B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
9 Health Care Stocks Whale Activity In Today’s Session - benzinga.com
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing - Stock Traders Daily
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue - webull.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Strong Buy Ratings And 15% Upside Potential - DirectorsTalk Interviews
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story? - Yahoo Finance
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results? - Yahoo Finance
Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon - Seeking Alpha
Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price - MarketBeat
Roivant Sciences Ltd (ROIV) Stock News Today - TradingKey
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Roivant Sciences Q1 Earnings Call Highlights - MarketBeat
Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
TD Cowen raises Roivant Sciences stock price target to $50 on execution - Investing.com South Africa
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside - TradingView
Roivant Sciences earnings beat by $0.04, revenue fell short of estimates - Investing.com
Roivant Sciences Releases Q1 2026 Financial Results - AlphaStreet
Earnings call transcript: Roivant posts Q1 2026 EPS beat, revenue miss as shares slip - Investing.com
Roivant Sciences shares rise despite revenue miss - Investing.com
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
ROIV: Strong cash reserves and major settlement boost, with key product launch on track for September - TradingView
Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines - marketscreener.com
Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
ROIV: Secured $950M from Moderna, advanced pivotal trials, and prepared for a key product launch - TradingView
Roivant Sciences shares rise despite revenue miss By Investing.com - Investing.com Australia
Roivant Sciences Ltd. 2026: Revenue $1.44M, EPS ($0.26) — 10-Q Summary - TradingView
Roivant Sciences (NASDAQ: ROIV) details $771.6M Moderna settlement windfall - Stock Titan
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $1.4M, vs. FactSet Est of $2.1M - marketscreener.com
Roivant reports Q1 loss, $3.9B cash and $290.6M net loss for quarter - TradingView
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update - marketscreener.com
Roivant earnings in focus as mosliciguat trial data looms By Investing.com - Investing.com Nigeria
Roivant earnings in focus as mosliciguat trial data looms - Investing.com
Arrowstreet Capital Limited Partnership Grows Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement System - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with a 14.74% Potential Upside - DirectorsTalk Interviews
Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
(ROIV) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Seven Fleet Capital Management LP Purchases New Shares in Roivant Sciences Ltd. $ROIV - MarketBeat
Janus Henderson Group PLC Purchases 177,339 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. Revenue Breakdown – NASDAQ:ROIV - TradingView
Roivant Sciences (ROIV) Expected to Post Quarterly Earnings on Thursday - MarketBeat
Form 4 Roivant Sciences Ltd. For: 29 July By Investing.com - Investing.com Nigeria
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):